NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback